Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01041521 · ClinicalTrials.gov registry record · Phase 4
The Impact of Omega Three Fatty Acids on Vascular Function in HIV
A Phase 4 study, sponsored by Tufts University.
- Completed
- Registry status
- Phase 4
- Development phase
- 129
- Enrollment target
NCT01041521 is a Phase 4 study that has completed, run by Tufts University. The registered enrollment target is 129 participants.
The verdict
NCT01041521, a Phase 4 study, has completed, sponsored by Tufts University.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 129 participants
- Enrollment target
Study Summary
The study seeks to determine if the use of omega three fatty acids in individuals infected with HIV and with high triglycerides leads to improved triglyceride levels, better blood vessel function and decrease in the amount of obstruction in blood vessels.
Interventions
- DRUG Lovaza
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 129 participants |
| Start Date | 2010-01 |
| Est. Completion | 2015-08 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01041521
The ClinicalTrials.gov registry entry for NCT01041521 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 129 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Tufts University, which has 163 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Lovaza is the first listed.
NCT01041521 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01041521 about?
NCT01041521 is a clinical study titled "The Impact of Omega Three Fatty Acids on Vascular Function in HIV". The study seeks to determine if the use of omega three fatty acids in individuals infected with HIV and with high triglycerides leads to improved triglyceride levels, better blood vessel function and decrease in the amount of obstruction in blood vessels.
What is the current status of trial NCT01041521?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 129 participants. The study started on 2010-01. Estimated completion is 2015-08.
What interventions are being tested in trial NCT01041521?
The interventions under investigation include: Lovaza (DRUG).
Who is sponsoring clinical trial NCT01041521?
This trial is sponsored by Tufts University, which has 163 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.